Alebund Pharmaceuticals (HKG:9637) obtained clearance for its investigational new drug application to initiate a clinical trial of AP308 from the U.S. Food and Drug Administration (FDA).
The drug will be studied for the treatment of IgA nephropathy, according to a Tuesday Hong Kong bourse filing.
The company intends to begin the trial soon.